April 2016

New Product - Repatha

Repatha (evolocumab (rch)) is a fully human IgG2 monoclonal antibody with high affinity binding to proprotein convertase subtilisin/kexin type 9 (PCSK9). Repatha inhibits circulating PCSK9 from binding to the low density lipoprotein (LDL) receptor on the liver cell surface, thus preventing PCSK9 mediated LDL receptor degradation. Increasing liver LDL receptor levels results in associated reductions in serum LDL cholesterol. Repatha is indicated as an adjunct to diet and exercise in adults with heterozygous familial hypercholesterolaemia (HeFH) or clinical atherosclerotic cardiovascular disease in combination with a statin or statin with other lipid lowering therapies, or in combination with other lipid lowering therapies in patients who are statin intolerant. Repatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia (HoFH) in combination with other lipid lowering therapies. Repatha 140 mg/mL solution for injection is available as a prefilled syringe (1’s) and prefilled pen (1’s, 2’s, 3’s).

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629